Abstract

This grant requests funds to support patient care activities, data collection, information exchange, and meeting travel for physicians participating in CALGB Group activities at Roswell Park Memorial Institute and the State University of New York at Buffalo. Participants represent medicine, surgery, radiation therapy, pathology, immunology, psychiatry, pharmacology, nursing, and data management specialties who will jointly evaluate new approaches to clinical cancer management as part of the cooperative Group program. Support for the participation of private practitioners in oncology is also sought through this grant, as are resources for extensive quality control activities for the primary and affiliate institutions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA002599-33
Application #
3555692
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1989-03-31
Budget Start
1987-04-01
Budget End
1989-03-31
Support Year
33
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263

  Publications

Stock, Wendy; Johnson, Jeffrey L; Stone, Richard M et al. (2013) Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer 119:90-8
Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Baer, M R; George, S L; Sanford, B L et al. (2011) Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 25:800-7
Salama, Joseph K; Stinchcombe, Thomas E; Gu, Lin et al. (2011) Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou Int J Radiat Oncol Biol Phys 81:e269-74
Kolitz, Jonathan E; George, Stephen L; Marcucci, Guido et al. (2010) P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116:1413-21
Yao, Song; Barlow, William E; Albain, Kathy S et al. (2010) Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 16:6169-76
Yao, Song; Barlow, William E; Albain, Kathy S et al. (2010) Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat 124:433-9
Garber, Judy E; Halabi, Susan; Tolaney, Sara M et al. (2010) Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 102:942-9
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Smith, S M; Johnson, J; Cheson, B D et al. (2009) Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-17

Showing the most recent 10 out of 84 publications